Clinical Trial Update: Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating TQ-B3101 for ROS1-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TQ-B3101 (TQ-B3101)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: ROS1-positive Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: UNKNOWN